Cellebrite DI (CLBT) Cost of Revenue (2020 - 2025)

Cellebrite DI's Cost of Revenue history runs 6 years deep, the most recent figure standing at $19.7 million for Q4 2025.

• On a quarterly basis, Cost of Revenue rose 11.73% year-over-year to $19.7 million in Q4 2025; TTM through Dec 2025 was $75.2 million, a 20.1% increase from a year earlier, with the FY2025 full-year figure at $75.2 million, up 20.1% from the prior year.
• Cost of Revenue slipped to $19.7 million in Q4 2025 per CLBT's latest filing, from $20.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $20.3 million in Q3 2025 and bottomed at $8.2 million in Q1 2021.
• The 5-year median for Cost of Revenue is $13.2 million (2022), against an average of $14.2 million.
• Across the five-year window, Cost of Revenue surged 33.96% in 2022 and retreated 11.39% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $12.3 million in 2021, then retreated by 1.66% to $12.1 million in 2022, then climbed by 22.96% to $14.9 million in 2023, then gained by 18.16% to $17.6 million in 2024, then rose by 11.73% to $19.7 million in 2025.
• Per Business Quant, the three latest CLBT Cost of Revenue figures stand at $19.7 million (Q4 2025), $20.3 million (Q3 2025), and $17.7 million (Q2 2025).